KIDFLAME COMBINATION PRODUCT TABLET

Indications

• Diabetes mellitus
• Hyperlipidemia
• Hypertension
• Gastrointestinal infections
• Inflammatory bowel disease
• Antimicrobial therapy

Dosage

Children: Refer to established herbal dosage guidelines, as specific dosing may vary based on formulation and indication.

Adults: Refer to established herbal dosage guidelines, as specific dosing may vary based on formulation and indication.

Mechanism of action

Berberine, the primary active component of Berberis, exerts its effects by activating AMP-activated protein kinase (AMPK), which plays a crucial role in cellular energy homeostasis. This activation leads to various downstream effects, including improved glucose metabolism, lipid metabolism, and anti-inflammatory responses. Additionally, berberine has demonstrated inhibitory effects on several pathogenic microorganisms and may modulate gut microbiota composition.

Pharmacodynamics

Berberine exhibits a broad spectrum of pharmacological activities, including antimicrobial, anti-inflammatory, and anti-diabetic effects. It has been shown to lower blood glucose levels, improve insulin sensitivity, and reduce cholesterol levels. Furthermore, its antioxidant properties help protect cells from oxidative stress.

Pharmacokinetics

Berberine has a low oral bioavailability due to extensive first-pass metabolism and poor absorption in the gastrointestinal tract. It is primarily metabolized in the liver and has a short half-life, necessitating multiple doses for sustained effects. The elimination of berberine occurs mainly through the feces. Berberine's pharmacokinetics can be influenced by gut microbiota, which can metabolize berberine into various metabolites.

Adverse effects

• Gastrointestinal disturbances
• Headaches
• Skin reactions
• Hypotension
• Dizziness

Interactions

• May interact with anticoagulants
• May enhance the effects of certain antihypertensive medications

Precautions

• Use with caution in patients with liver or kidney disorders
• Monitor blood pressure in patients using antihypertensive drugs

Pregnancy

Safety during pregnancy has not been established; use only if clearly needed.

Breast-feeding

Not recommended during breastfeeding due to lack of safety data.

Storage

Store in a cool, dry place away from light.

Formulations

• Powder
• Capsules
• Tinctures
• Extracts

Indications

• Blistering skin conditions
• Certain types of warts and papillomas
• As a counterirritant in some topical formulations

Dosage

Children: Refer to established clinical guidelines or product-specific information as dosages can vary widely based on indication and formulation.

Adults: Refer to established clinical guidelines or product-specific information as dosages can vary widely based on indication and formulation.

Mechanism of action

Cantharidin, the active compound in cantharis, acts mainly as a protein phosphatase inhibitor. This inhibition leads to the disruption of cellular signaling pathways, promoting apoptosis in certain cells. The irritant properties of cantharidin also stimulate local blood flow and promote the formation of blisters, which has been utilized in some therapeutic applications.

Pharmacodynamics

Cantharis exhibits a range of pharmacological effects, including diuretic activity, which is attributed to increased renal blood flow and altered nephron function. Its irritant properties can lead to local inflammation and blister formation, which may be beneficial in some dermatological conditions. However, the use of cantharis is associated with toxicity, including renal damage and gastrointestinal irritation, highlighting the need for caution.

Pharmacokinetics

Cantharidin is rapidly absorbed through the gastrointestinal tract, with peak plasma concentrations occurring shortly after ingestion. It is metabolized in the liver, and its effects can vary based on dosage and route of administration. The elimination half-life of cantharidin is not well defined, but it is known to be excreted primarily in urine. The systemic absorption can lead to potential toxicity, particularly at higher doses.

Contra-indications

• Hypersensitivity to cantharis or any of its components
• Severe kidney disease
• Active gastrointestinal ulcers

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Burning sensation in the throat
• Renal toxicity
• Hematuria
• Dermatitis

Interactions

• Concurrent use with nephrotoxic drugs may increase the risk of kidney damage
• Can enhance the effects of other irritants or diuretics

Precautions

• Use cautiously in patients with a history of kidney problems
• Should not be used in children without medical supervision
• Monitor for signs of toxicity, especially in high doses

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed and if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether cantharis is excreted in human milk. Caution is advised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Topical ointments
• Tinctures
• Homeopathic preparations

Indications

• Inflammation
• Digestive disorders
• Hormonal imbalance
• Diabetes management
• Weight management

Dosage

Children: Refer to established guidelines or consult a healthcare provider for specific dosing recommendations.

Adults: Refer to established guidelines or consult a healthcare provider for specific dosing recommendations.

Mechanism of action

Dioscorea is thought to exert its effects through several mechanisms, including the modulation of steroid hormone metabolism and the promotion of insulin sensitivity. Certain compounds found in Dioscorea, such as diosgenin, may mimic the action of hormones and contribute to its therapeutic effects. Additionally, Dioscorea may possess antioxidant properties that help to reduce oxidative stress in the body.

Pharmacodynamics

The pharmacodynamics of Dioscorea are primarily related to its bioactive constituents, which include saponins, alkaloids, and flavonoids. These compounds can influence various biological pathways, including those related to inflammation, glucose metabolism, and hormonal balance. The anti-inflammatory properties may contribute to its use in treating conditions like arthritis and other inflammatory diseases.

Pharmacokinetics

Dioscorea's pharmacokinetics are not fully characterized, but it is known that the bioactive compounds are absorbed through the gastrointestinal tract following ingestion. The metabolism of these compounds may occur in the liver, leading to various metabolites that can exert biological effects. The excretion pathways remain largely undefined, but it is presumed that metabolites are eliminated through urine and feces.

Pregnancy

There is insufficient data to determine the safety of Dioscorea during pregnancy. Caution is advised.

Breast-feeding

Limited information is available regarding the safety of Dioscorea during breastfeeding. Consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Urinary tract infections
• Bladder inflammation
• Kidney stones
• Diuretic therapy
• Supportive treatment for prostate issues

Dosage

Children: Refer to established herbal guidelines as specific dosing for maydis in children is not standardized.

Adults: Refer to established herbal guidelines as specific dosing for maydis is not standardized.

Mechanism of action

Maydis is believed to exert its effects primarily through its diuretic properties. It may enhance renal function by increasing glomerular filtration rate and promoting the excretion of water and solutes. The presence of various bioactive compounds, such as flavonoids and saponins, may contribute to its anti-inflammatory effects, helping to soothe the urinary tract.

Pharmacodynamics

The pharmacodynamics of maydis are linked to its ability to modulate fluid balance and reduce inflammation. It promotes urination, which can help in flushing out pathogens in urinary tract infections. Additionally, its anti-inflammatory properties may reduce symptoms associated with bladder irritation and discomfort.

Pharmacokinetics

The pharmacokinetics of maydis, including absorption, distribution, metabolism, and excretion, are not well-documented in clinical studies. However, as a herbal remedy, it is assumed that the active constituents are absorbed in the gastrointestinal tract, with possible metabolism in the liver. The diuretic effects generally occur relatively quickly after administration, but specific half-life and elimination pathways are not clearly established in the literature.

Pregnancy

There is limited information on the safety of maydis during pregnancy. It is recommended to use it only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is unclear whether maydis is excreted in human milk. Caution is advised when administering to breastfeeding women.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Culinary use as a flavoring agent
• Possible diuretic support
• Antioxidant support
• Nutritional supplementation

Dosage

Children: Refer to established herbal guidelines or consult a healthcare provider for appropriate pediatric dosages.

Adults: Refer to established herbal guidelines or consult a healthcare provider for appropriate culinary and therapeutic dosages.

Mechanism of action

The active components of petroselinum, particularly flavonoids, carotenoids, and essential oils, contribute to its biological effects. These compounds exhibit antioxidant properties, which help in neutralizing free radicals in the body. Additionally, some studies suggest that parsley may influence the activity of certain enzymes involved in detoxification processes.

Pharmacodynamics

Petroselinum may exhibit diuretic effects, promoting increased urine production and aiding in the elimination of excess fluids from the body. It also contains compounds that may have anti-inflammatory and antimicrobial properties, contributing to overall health benefits. Its rich vitamin K content plays a role in bone health and blood clotting.

Pharmacokinetics

The pharmacokinetics of petroselinum are not well-characterized in the literature. However, it is known that the bioactive compounds are absorbed in the gastrointestinal tract, with varying degrees of bioavailability depending on the compound. Metabolism primarily occurs in the liver, and elimination may involve renal excretion of metabolites.

Pregnancy

Petroselinum (parsley) is generally considered safe in food amounts during pregnancy, but high doses should be avoided due to potential uterine stimulation.

Breast-feeding

Petroselinum is likely safe in food amounts during breastfeeding, but excessive amounts should be avoided.

Storage

Store in a cool, dry place. Fresh parsley should be kept in the refrigerator and used within a week for best quality.

Formulations

• Fresh leaves
• Dried leaves
• Essential oil
• Extracts

Indications

• Hyperlipidemia
• Cardiovascular disease prevention
• Cholesterol management
• Dietary supplement for overall health

Dosage

Children: Refer to specific product guidelines, as safety and efficacy in children have not been established.

Adults: Refer to specific product guidelines as dosages may vary based on formulation and intended use. Generally, doses range from 1 to 3 grams per day when used as a dietary supplement.

Mechanism of action

Stigmata exerts its effects primarily by inhibiting the absorption of cholesterol in the intestine and promoting its excretion. It competes with cholesterol for incorporation into micelles, thus reducing the amount of cholesterol available for absorption. Additionally, it may exert anti-inflammatory effects through modulation of various signaling pathways, including the inhibition of nuclear factor kappa B (NF-kB) and other inflammatory mediators.

Pharmacodynamics

The pharmacodynamics of stigmata are characterized by its ability to influence lipid metabolism and inflammation. By reducing intestinal cholesterol absorption, it leads to lower serum cholesterol levels, particularly low-density lipoprotein (LDL) cholesterol. Its anti-inflammatory effects may contribute to the overall cardiovascular benefits observed with its use. The exact dose-response relationship and timing of effects can vary depending on individual metabolic factors.

Pharmacokinetics

Stigmata is well absorbed in the gastrointestinal tract, with peak plasma concentrations typically reached within a few hours after ingestion. It undergoes metabolism primarily in the liver, where it is converted into various metabolites. The elimination half-life and specific metabolic pathways have not been extensively characterized in human studies, but its excretion occurs predominantly via feces, with minimal urinary excretion.

Pregnancy

Stigmata is not well studied in pregnant populations. It is recommended to avoid use unless benefits outweigh risks.

Breast-feeding

Due to insufficient data on the excretion of stigmata in breast milk, caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Warts
• Skin infections
• Respiratory issues
• Inflammation
• Fungal infections

Dosage

Children: Refer to established herbal guidelines or consult a healthcare provider for dosing recommendations.

Adults: Refer to established herbal guidelines or consult a healthcare provider for dosing recommendations.

Mechanism of action

The exact mechanism of action of thuja is not well defined. However, it is thought to exert its effects through immunomodulatory actions, potentially enhancing the immune response against certain pathogens. Compounds found in thuja, such as thujaplicin, may also have antifungal and antibacterial properties, contributing to its traditional use in treating skin conditions.

Pharmacodynamics

Thuja is believed to interact with the immune system, promoting a response that may help in the clearance of infections or abnormal growths, such as warts. Its active compounds may also exhibit cytotoxic effects against certain cells, although detailed pharmacodynamic studies are limited. The plant's extracts may influence inflammatory pathways, although specific pathways remain to be fully elucidated.

Pharmacokinetics

The pharmacokinetics of thuja are not well characterized. It is generally administered as an extract, tincture, or homeopathic preparation, and the absorption, distribution, metabolism, and excretion of its active constituents can vary widely. Due to its herbal nature, the bioavailability and half-life of thuja compounds are not well documented, and further research is needed to understand these aspects thoroughly.

Pregnancy

There is insufficient data on the safety of thuja during pregnancy. It is advisable to avoid use unless directed by a healthcare provider.

Breast-feeding

Due to a lack of safety data, thuja should be used with caution while breastfeeding, and only if deemed necessary by a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Dissolution of cholesterol gallstones
• Management of primary biliary cholangitis
• Prevention of gallstone formation in patients undergoing rapid weight loss
• Treatment of certain types of liver disease

Dosage

Adults: The usual dose in adults for the treatment of gallstones is 8-10 mg/kg/day, divided into two or three doses. For primary biliary cholangitis, the recommended dose is 13-15

Mechanism of action

Ursodiol acts by reducing the hepatic synthesis of cholesterol, thereby decreasing the amount of cholesterol secreted into the bile. This action leads to an increase in bile acid concentrations, which promotes the solubilization of cholesterol in bile and helps to dissolve existing cholesterol gallstones. It also has immunomodulatory effects and may improve liver function by enhancing bile flow and reducing the toxic effects of bile acids on hepatocytes.

Pharmacodynamics

Ursodiol exhibits a dose-dependent effect on bile acid synthesis and cholesterol metabolism. It reduces the biliary cholesterol saturation index, leading to a decrease in cholesterol crystallization and promoting gallstone dissolution. Ursodiol also has anti-inflammatory properties, which can mitigate the inflammatory processes associated with liver diseases. Furthermore, it stimulates the secretion of bile, enhancing the digestive process and aiding in the absorption of dietary fats.

Pharmacokinetics

Ursodiol is well absorbed from the gastrointestinal tract after oral administration. It undergoes enterohepatic recirculation, where it is reabsorbed in the intestines and returned to the liver. The peak plasma concentration occurs approximately 1-3 hours after ingestion. The elimination half-life of ursodiol is about 3-4 hours, and it is primarily excreted in the bile. The drug's pharmacokinetics may be influenced by liver function and gastrointestinal transit time.

Pregnancy

There is limited data on the safety of arbutin during pregnancy. Consultation with a healthcare provider is recommended before use.

Breast-feeding

Limited data is available on the excretion of arbutin in breast milk. Caution is advised; consult a healthcare provider.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Topical creams
• Lotions
• Serums

Indications

• Inflammation
• Pain management
• Diuretic therapy
• Traditional medicine applications

Dosage

Children: Refer to established clinical guidelines and literature for appropriate dosing, as specific dosing for vesicaria in paediatric populations is not well-defined.

Adults: Refer to established clinical guidelines and literature for appropriate dosing, as specific dosing for vesicaria is not well-defined.

Mechanism of action

The active compounds in vesicaria may interact with various biological pathways, including modulation of inflammatory mediators and inhibition of pain pathways. Specific mechanisms may involve the modulation of cyclooxygenase (COX) enzymes, leading to reduced synthesis of prostaglandins, which play a key role in pain and inflammation.

Pharmacodynamics

The pharmacodynamic properties of vesicaria are not extensively characterized in clinical literature. However, its effects are believed to stem from its ability to influence neurotransmitter systems and inflammatory pathways. This may lead to analgesic effects and the reduction of inflammation in affected tissues.

Pharmacokinetics

The pharmacokinetics of vesicaria are not well documented due to limited clinical studies. Absorption, distribution, metabolism, and excretion characteristics remain largely unknown. Further research is needed to clarify how its active compounds are processed in the body.

Pregnancy

Safety during pregnancy has not been established. Use only if clearly needed and the benefits outweigh potential risks.

Breast-feeding

Caution is advised. Limited data available on excretion in breast milk.

Storage

Store in a cool, dry place away from light and moisture.

Mechanism of action

Arbutin is a hydroquinone glycoside, however the hydroquinone moiety is not solely responsible for the de-pigmentating actions of arbutin. It acts as a competitive inhibitor of tyrosinase enzyme by acting on the L-tyrosine binding site to suppress melanogenesis and mediate its de-pigmenting actions on human skin. Tyrosinase is an enzyme involved in the regulation of rate-limiting steps during the synthesis of melanin; it regulates the conversion of L-tyrosine into L-dopa, and subsequent conversion of L-dopa to L-dopaquinone. Via inhibition of tyrosinase activity in a concentration-dependent manner, arbutin attenuates the production of melanin in melanocytes. While most studies suggest that arbutin has negligible effect on the tyrosinase mRNA expression, a study assessing the effect of arbutin on melanocyte differentiation inducement system using ES cells propose that arbutin may also downregulate the expression of tyrosinase in addition to its inhibitory action on the enzyme. The contradictory findings across studies may be due to previous studies using terminally-differentiated melanocytes and melanoma cells. ...This study ... presents evidence that cotreatment of aloesin and arbutin inhibits tyrosinase activity in a synergistic manner by acting through a different action mechanism. Aloesin or arbutin similarly inhibited enzyme activity of human- and mushroom-tyrosinases with an IC50 value of 0.1 or 0.04 mM, respectively. Lineweaver-Burk plots of the enzyme kinetics data showed that aloesin inhibited tyrosinase activity noncompetitively with a Ki value of 5.3 mM, whereas arbutin did it competitively (Maeda, 1996). We then examined whether cotreatment of these agents inhibits the tyrosinase activity in a synergistic manner. The results showed that 0.01 mM aloesin in the presence of 0.03 mM arbutin inhibited activity of mushroom by 80% of the control value and the reverse was also true. The inhibitory effects were calculated to be synergistic according to the Burgi method. Taken together, we suggest that aloesin along with arbutin inhibits in synergy melanin production by combined mechanisms of noncompetitive and competitive inhibitions of tyrosinase activity.

Pharmacodynamics

At non-toxic concentrations, arbutin inhibited the activity of tyrosinase in cultured human keratinocytes, while having minimal effect on the expression of tyrosinase mRNA or the synthesis of the enzyme. α-Arbutin produced a concentration-dependent inhibition of melanin synthesis of human melanoma cells, HMV-II. No inhibitory effect on HMV-II cell growth was seen at concentrations lower than 1.0 mM. At concentrations of 0.5 mM of arbutin, tyrosinase activity was reduced to 60% of that in non-treated cells. The addition of arbutin blocked and inhibited α-MSH-stimulated melanogenesis in B16 melanoma cells, brownish guinea pig, and human skin tissue. In a pilot study of healthy male adults exposed to UV B irradiation, topical administration of arbutin inhibited UV-induced nuclear factor-kappaB activation in human keratinocytes. In mouse skin, arbutin counteracted oxidative stress induced by 12-O-tetradecanoylphorbol-13-acetate.